Investors Should Not Hesitate to Buy: Sibanye Gold Limited (SBGL), Tandem Diabetes Care, Inc. (TNDM)

Sibanye Gold Limited (SBGL) rose 10.93% this week, a trend that has led to both investors and traders taking note of the stock. Over the past one year, the equity price has embarked on a drop that has seen it decline -2.93% and is now up by 43.46% since start of this year. A look at its monthly performance shows that the stock has recorded a 41.96% gain over the past 30 days. Its equity price climbed by 70.59% over the past three months which led to its overall six-month increase to stand at 65.71%.

Experts from research firms are bullish about the near-term performance of Sibanye Gold Limited with most of them predicting a $5.71 price target on a short-term (12 months) basis. The average price target by the analysts will see a 40.64% rise in the stock and would lead to SBGL’s market cap to surge to $2.92B. The stock has been rated an average 0, which roughly stands towards the bullish end of the spectrum. Reuters looked into the 1 analysts that track Sibanye Gold Limited (NYSE:SBGL) and find out that 0 of them rated it as a Hold. 1 of the 1 analysts rated it as a Buy or a Strong Buy while 0 advised investors to desist from buying the stock or sell it if they already possess it.

A look at SBGL technical analysis shows that its 14-day Relative Strength Index (RSI) is in a neutral zone after reaching 67.3 point. Its trading volume has lost -1184833 shares compared to readings over the past three months as it recently exchanged 2755167 shares. This means there is reduced activity from short-term traders as per session, its average trading volume is 3940000 shares, and this is 0.7 times the normal volume.

The price of Tandem Diabetes Care, Inc. (NASDAQ:TNDM) currently stands at $46.22 after it went down by $-0.23 or -0.5% and has found a strong support at $44.69 a share. If the TNDM price drops below that critical support, then it would lead to a bearish trend. In the short-term, a dip below the $43.17 mark would also be bad for the stock as it means that the stock would plunge by 6.6% from its current position. However, if the stock price is able to trade above the resistance point around $47.5, then it could likely surge higher to try and break the upward resistance which stands at $48.79 a share. Its average daily volatility over the past one month stands at 5.21%. The stock has plunged by 3.83% from its 52-weeks high of $44.45 which it reached on Sep. 13, 2018. In general, it is 95.13% above its 52-weeks lowest point which stands at $2.25 and this setback was observed on Feb. 15, 2018.

Analysts have predicted a price target for Tandem Diabetes Care, Inc. (TNDM) for 1 year and it stands at an average $50.45/share. This means that it would likely increase by 9.15% from its current position. The current price of the stock has been moving between $44.45 and $47.26. Some brokerage firms have a lower target for the stock than the average, with one of them setting a price target as low as $36. On the other hand, one analyst is super bullish about the price, setting a target as high as $60.

Analysts view Tandem Diabetes Care, Inc. (NASDAQ:TNDM) as a Buy, with 2 consensus rating. Reuters surveyed 11 analysts that follow TNDM and found that 3 of those analysts rated the stock as a Hold. The remaining 8 were divided, with 8 analyst rating it as a Buy or a Strong Buy while 0 analysts advised investors to desist from buying Tandem Diabetes Care, Inc. (TNDM) shares or sell it if they already own it.